Ashley Moore Drake

Ashley Moore Drake

Ashley Moore Drake
Washington, DC
+1 202 346 4192

Ashley Moore Drake is a senior associate in Goodwin’s Complex Litigation & Dispute Resolution practice. Ashley assists clients in a variety of complex litigation matters in both federal and state court, including general commercial litigation and antitrust class action litigation. Ashley has also represented clients before and assisted in responding to inquiries from federal and state regulators, including the DOJ, FINRA, SEC, and FTC. In addition, she had conducted internal corporate investigations for companies and their boards. Ashley’s clients include healthcare startups, drug manufacturers, public and private life sciences companies, and financial institutions.


Ashley’s recent representations include:

  • Representing a drug manufacturer in a dispute against a competitor involving Lanham Act, unfair competition claims, and other business torts
  • Representing a clinical research company in litigation concerning post-acquisition earnout payments
  • Represented a generic drug manufacturer in an antitrust reverse payment case in the U.S. District Court for the Northern District of California, securing a verdict for the client following a six-week jury trial
  • Represented a healthcare technology startup in a jury trial against a pharmacy benefits manager in the U.S. District Court for the Northern District of California
  • Represented a generic drug manufacturer in an antitrust reverse payment case in the U.S. District Court for the Southern District of New York, resulting in a full dismissal at the motion to dismiss stage
  • Represented an investment bank in the SEC inquiry of SPAC underwriting practices
  • Represented the board of a real estate investment trust in an SEC inquiry concerning the relationship with its asset manager
  • Represented life sciences companies in responding to SEC inquiries concerning insider trading
  • Defended a food container manufacturer in an arbitration concerning a decades-long supply agreement. The dispute was successfully resolved at the summary judgment stage
  • Represented a former pharmaceutical company executive in a criminal anti-kickback case in the U.S. District Court for the District of Massachusetts, resulting in an acquittal following a month-long jury trial

Pro Bono:

  • Successfully overturned a murder conviction and life sentence for a client who served 20 years in prison for a crime that he did not commit. After the conviction was overturned, Ashley successfully pursued and obtained compensation for the client under 42 U.S.C. § 1983 and Massachusetts ch. 258D (the erroneous conviction statute)
  • In partnership with GLBTQ Legal Advocates & Defenders (GLAD) and Prisoner Legal Services (PLS), Ashley represented a transgender woman incarcerated in a men’s prison in Massachusetts. As a result, the client was transferred to a women’s facility, the first transfer of its kind in the United States
  • Represented non-violent offenders serving federal prison sentences in seeking compassionate release during the COVID-19 pandemic

Professional Activities

Ashley is a member of the Boston Bar Association.




Howard University School of Law

(cum laude)


University of Virginia



  • Massachusetts
  • District of Columbia


  • U.S. District Court for the District of Massachusetts

Recognition & Awards

Ashley has been recognized by The Best Lawyers in America Ones to Watch for her work in Commercial Litigation 2022.

Ashley was named to The Best Lawyers in America 2021: Ones to Watch.

In 2020, Ashley was awarded the Arc of Justice Award by the New England Innocence Project for her work on behalf of the wrongfully convicted. Also in 2020, Ashley received Goodwin’s Robert B. Fraser Pro Bono Award for her commitment to pro bono work.

In 2023, the City of Boston recognized Ashley for her outstanding service and advocacy in connection with overturning wrongful convictions.


Ashley co-authored the articles “Get It In Writing: Deducting False Claims Act Payment,” Business Crimes Bulletin (November 2018), and “PE Investment in Health Care Attracting Greater Federal Scrutiny,” New York Law Journal (June 2021).